(Q37179388)

18 August 2017

1 reference

title

Current status of therapy for chronic myeloid leukemia: a review of drug development (English)

1 reference

18 August 2017

main subject

chronic myeloid leukemia

0 references

4

Francis Giles

1 reference

18 August 2017

Swami Padmanabhan

1

1 reference

18 August 2017

Saritha Ravella

series ordinal

2

1 reference

18 August 2017

Tyler Curiel

series ordinal

3

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

359-377

1 reference

18 August 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Regulation of proplatelet formation and platelet release by integrin alpha IIb beta3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Discontinuation of imatinib therapy after achieving a molecular response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

The role of interferon-alpha in the treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Induction of centrosome and chromosome aberrations by imatinib in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.359

21 January 2018

Identifiers

DOI

10.2217/14796694.4.3.359

1 reference

18 August 2017

1 reference